Researchers have developed an algorithm to identify people with metabolic dysfunction-associated steatotic liver disease (MASLD), a type of fatty liver disease, based on information…
News
BILIARY ATRESIA
NewsPatient identification guidelines may help diagnose biliary atresia earlier
A team of experts in the U.S. and Canada have developed patient identification guidelines to help pediatric primary care providers, or PCPs, in making an…
A single dose of Precision BioSciences’ investigational gene-editing therapy PBGENE-HBV was well tolerated and showed early signs of antiviral activity among three adults with…
CHOLANGITIS
News2nd liver transplant linked to good outcomes in PSC
A second liver transplant results in transplant and patient outcomes in people with primary sclerosing cholangitis (PSC) that are comparable or better than those…
CHOLESTASIS
NewsAI models may aid intrahepatic cholestasis of pregnancy prediction
New artificial intelligence (AI) models based on 11 possible risk factors of intrahepatic cholestasis of pregnancy (ICP) can accurately distinguish between healthy pregnant women,…
FATTY LIVER DISEASE
NewsPhase 2 trial of DD01 in treating MASH completes enrollment
D&D Pharmatech has finished enrolling a Phase 2 clinical trial of its experimental therapy DD01 in overweight or obese adults with metabolic dysfunction-associated steatohepatitis…
ALAGILLE SYNDROME
NewsPoor access to genetic testing may delay Alagille syndrome diagnosis
Difficulty accessing genetic testing in low- to middle-income countries may delay the diagnosis of Alagille syndrome in children and lead to misdiagnoses that may…
HEPATITIS
NewsDosing complete in Phase 2b trial of AHB-137 for hepatitis B
A Phase 2b clinical trial testing AusperBio’s investigational therapy AHB-137 in people with chronic hepatitis B has completed dosing and is now unblinded,…
CHOLANGITIS
NewsAntibiotic may ease IBD related to primary sclerosing cholangitis
Four weeks of treatment with vancomycin, a common antibiotic, lowered inflammatory bowel disease (IBD) in people with primary sclerosing cholangitis (PSC), data from a…
CHOLESTASIS
NewsLivmarli, Bylvay safely reduce pruritus in PFIC, Alagille children
Livmarli (maralixibat) and Bylvay (odevixibat) can help relieve itching, or pruritus, and reduce liver damage in children with progressive familial intrahepatic cholestasis (PFIC) or…
Recent Posts
- Getting ahead of concerns about fatty liver disease in children
- Early trial results testing maralixibat for hard-to-treat itching due by year’s end
- My child with Alagille syndrome is going through a ‘picky eater’ phase
- Biliary atresia treatment AX-0810 faring well in early testing
- Clinical trial results support bepirovirsen for hepatitis B